UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 532

Sortiert nach

A Pituitary Society update to acromegaly management guidelines

Pituitary, 2021-02, Vol.24 (1), p.1-13

2021

Volltextzugriff (PDF)

Administration of Acylated Ghrelin Reduces Insulin Sensitivity, Whereas the Combination of Acylated Plus Unacylated Ghrelin Strongly Improves Insulin Sensitivity

The journal of clinical endocrinology and metabolism, 2004-10, Vol.89 (10), p.5035-5042

2004

Volltextzugriff (PDF)

Ghrelin and unacylated ghrelin stimulate human osteoblast growth via mitogen-activated protein kinase (MAPK)/phosphoinositide 3-kinase (PI3K) pathways in the absence of GHS-R1a

Journal of endocrinology, 2006-01, Vol.188 (1), p.37-47

2006

Volltextzugriff (PDF)

The Hypercoagulable State in Cushing's Disease Is Associated with Increased Levels of Procoagulant Factors and Impaired Fibrinolysis, But Is Not Reversible after Short-Term Biochemical Remission Induced by Medical Therapy

The journal of clinical endocrinology and metabolism, 2012-04, Vol.97 (4), p.1303-1310

2012

Volltextzugriff (PDF)

Differentiating between Cushing's disease and pseudo-Cushing's syndrome: comparison of four tests

European journal of endocrinology, 2014-04, Vol.170 (4), p.477

2014

Volltextzugriff (PDF)

Cerebrovascular Events, Secondary Intracranial Tumors, and Mortality After Radiotherapy for Nonfunctioning Pituitary Adenomas: A Subanalysis From the Dutch National Registry of Growth Hormone Treatment in Adults

The journal of clinical endocrinology and metabolism, 2015-03, Vol.100 (3), p.1104-1112

2015

Volltextzugriff (PDF)

Non-Acylated Ghrelin Counteracts the Metabolic But Not the Neuroendocrine Response to Acylated Ghrelin in Humans

The journal of clinical endocrinology and metabolism, 2004-06, Vol.89 (6), p.3062-3065

2004

Volltextzugriff (PDF)

Safety, tolerability, pharmacokinetics and pharmacodynamics of AZP-531, a first-in-class analogue of unacylated ghrelin, in healthy and overweight/obese subjects and subjects with type 2 diabetes

Diabetes, obesity & metabolism, 2016-09, Vol.18 (9), p.868-874

2016

Volltextzugriff (PDF)

Effects of Ghrelin on the Insulin and Glycemic Responses to Glucose, Arginine, or Free Fatty Acids Load in Humans

The journal of clinical endocrinology and metabolism, 2003-09, Vol.88 (9), p.4268-4272

2003

Volltextzugriff (PDF)

Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients

European journal of endocrinology, 2009-04, Vol.160 (4), p.529

2009

Volltextzugriff (PDF)

Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly

The Lancet (British edition), 2005-05, Vol.365 (9471), p.1644-1646

2005

Volltextzugriff (PDF)

Long-Term Safety of Pegvisomant in Patients with Acromegaly: Comprehensive Review of 1288 Subjects in ACROSTUDY

Pharmacotherapy, 2012-05, Vol.97 (5), p.1589-1597

2012

Volltextzugriff (PDF)

Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study

The journal of clinical endocrinology and metabolism, 2014-03, Vol.99 (3), p.791-799

2014

Volltextzugriff (PDF)

Consensus on criteria for acromegaly diagnosis and remission

Pituitary, 2024-02, Vol.27 (1), p.7-22

2024

Volltextzugriff (PDF)

Ghrelin and glucose homeostasis

Peptides (New York, N.Y. : 1980), 2011-11, Vol.32 (11), p.2309-2318

2011

Volltextzugriff (PDF)

Pituitary insufficiency

The Lancet (British edition), 1998-07, Vol.352 (9122), p.127-134

1998

Volltextzugriff (PDF)

Correction: consensus on criteria for acromegaly diagnosis and remission

Pituitary, 2024-02, Vol.27 (1), p.88-88

2024

Volltextzugriff (PDF)

Pilot study to define criteria for Pituitary Tumors Centers of Excellence (PTCOE): results of an audit of leading international centers

Pituitary, 2023-10, Vol.26 (5), p.583-596

2023

Volltextzugriff (PDF)

Efficacy and safety of bariatric surgery for craniopharyngioma-related hypothalamic obesity: a matched case-control study with 2 years of follow-up

International Journal of Obesity, 2017-02, Vol.41 (2), p.210-216

2017

Volltextzugriff (PDF)

Long-Term Efficacy and Safety of Pegvisomant in Combination With Long-Acting Somatostatin Analogs in Acromegaly

The journal of clinical endocrinology and metabolism, 2014-10, Vol.99 (10), p.3644-3652

2014

Volltextzugriff (PDF)

Standards of care for medical management of acromegaly in pituitary tumor centers of excellence (PTCOE)

Pituitary, 2024-08, Vol.27 (4), p.381-388

2024

Volltextzugriff (PDF)

Ghrelin and its unacylated isoform stimulate the growth of adrenocortical tumor cells via an anti-apoptotic pathway

American journal of physiology: endocrinology and metabolism, 2007-07, Vol.293 (1), p.E302-E309

2007

Volltextzugriff (PDF)

Metabolic effects of overnight continuous infusion of unacylated ghrelin in humans

European journal of endocrinology, 2012-05, Vol.166 (5), p.911

2012

Volltextzugriff (PDF)

The endocrine response to acute ghrelin administration is blunted in patients with anorexia nervosa, a ghrelin hypersecretory state

Clinical endocrinology (Oxford), 2004-05, Vol.60 (5), p.592-599

2004

Volltextzugriff (PDF)

Postoperative Evaluation of Patients with Acromegaly: Clinical Significance and Timing of Oral Glucose Tolerance Testing and Measurement of (Free) Insulin-Like Growth Factor I, Acid-Labile Subunit, and Growth Hormone-Binding Protein Levels

The journal of clinical endocrinology and metabolism, 2005-12, Vol.90 (12), p.6480-6489

2005

Volltextzugriff (PDF)

1 – 25 von 532

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(492)
Mit Volltextzugriff
(439)

Publikationsform

Sprache

5 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(380)
Life Sciences & Biomedicine
(373)
Humans
(341)
Endocrinology & Metabolism
(221)
Male
(203)
Female
(190)
Adult
(162)
Biological And Medical Sciences
(159)
Medical Sciences
(140)
Middle Aged
(120)
Aged
(67)
Fundamental And Applied Biological Sciences. Psychology
(67)
Acromegaly - Drug Therapy
(66)
Endocrinology
(65)
Endocrinopathies
(62)
Vertebrates: Endocrinology
(60)
Acromegaly
(56)
Adolescent
(56)
Somatostatin - Analogs & Derivatives
(56)
Child
(48)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

A Pituitary Society update to acromegaly management guidelines

Administration of Acylated Ghrelin Reduces Insulin Sensitivity, Whereas the Combination of Acylated Plus Unacylated Ghrelin Strongly Improves Insulin Sensitivity

Ghrelin and unacylated ghrelin stimulate human osteoblast growth via mitogen-activated protein kinase (MAPK)/phosphoinositide 3-kinase (PI3K) pathways in the absence of GHS-R1a

The Hypercoagulable State in Cushing's Disease Is Associated with Increased Levels of Procoagulant Factors and Impaired Fibrinolysis, But Is Not Reversible after Short-Term Biochemical Remission Induced by Medical Therapy

Differentiating between Cushing's disease and pseudo-Cushing's syndrome: comparison of four tests

Cerebrovascular Events, Secondary Intracranial Tumors, and Mortality After Radiotherapy for Nonfunctioning Pituitary Adenomas: A Subanalysis From the Dutch National Registry of Growth Hormone Treatment in Adults

Non-Acylated Ghrelin Counteracts the Metabolic But Not the Neuroendocrine Response to Acylated Ghrelin in Humans

Safety, tolerability, pharmacokinetics and pharmacodynamics of AZP-531, a first-in-class analogue of unacylated ghrelin, in healthy and overweight/obese subjects and subjects with type 2 diabetes

Effects of Ghrelin on the Insulin and Glycemic Responses to Glucose, Arginine, or Free Fatty Acids Load in Humans

Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients

Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly

Long-Term Safety of Pegvisomant in Patients with Acromegaly: Comprehensive Review of 1288 Subjects in ACROSTUDY

Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study

Consensus on criteria for acromegaly diagnosis and remission

Ghrelin and glucose homeostasis

Pituitary insufficiency

Correction: consensus on criteria for acromegaly diagnosis and remission

Pilot study to define criteria for Pituitary Tumors Centers of Excellence (PTCOE): results of an audit of leading international centers

Efficacy and safety of bariatric surgery for craniopharyngioma-related hypothalamic obesity: a matched case-control study with 2 years of follow-up

Long-Term Efficacy and Safety of Pegvisomant in Combination With Long-Acting Somatostatin Analogs in Acromegaly

Standards of care for medical management of acromegaly in pituitary tumor centers of excellence (PTCOE)

Ghrelin and its unacylated isoform stimulate the growth of adrenocortical tumor cells via an anti-apoptotic pathway

Metabolic effects of overnight continuous infusion of unacylated ghrelin in humans

The endocrine response to acute ghrelin administration is blunted in patients with anorexia nervosa, a ghrelin hypersecretory state

Postoperative Evaluation of Patients with Acromegaly: Clinical Significance and Timing of Oral Glucose Tolerance Testing and Measurement of (Free) Insulin-Like Growth Factor I, Acid-Labile Subunit, and Growth Hormone-Binding Protein Levels

Suchergebnisse filtern